Mr. Zakrzewski has over 25 years of experience as an executive in the biotechnology and pharmaceutical
industry. He currently serves on the Board of Directors of publicly held companies Acceleron
Pharmaceuticals, Amarin Pharmaceuticals, Onxeo S.A., and Sangamo Therapeutics. Mr Zakrzewski also
serves on the board of a number of privately held companies, is the founder of a number of
biotechnology companies, and is involved in a number of philanthropic activities. He was Chairman and
CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and
commercialization of cardiovascular drugs based on Omega 3‘s from 2010 to 2013, successfully
developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, in 2010
and 2011. Prior to this, he was Chairman, President & Chief Executive Officer of Xcellerex, a privately
held company focusing on commercializing its proprietary next generation manufacturing technology for
biotherapeutics and vaccines from 2007 to 2010. Xcellerex was sold to GE Healthcare. Mr. Zakrzewski
also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical
company focused on cardiovascular drugs from 2005 to 2007. Mr. Zakrzewski had responsibility for the
company’s pharmaceutical operations including, R&D, business development, supply
chain/manufacturing, quality, IT, and compliance. Reliant Pharmaceuticals was sold to GlaxoSmithKline
in 2007. Prior to this, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly &
Company for 17 years including R&D, manufacturing, finance and business development. His most
recent position, Senior Vice President, had global responsibility for all business and corporate
development. Mr. Zakrzewski, an inventor on multiple US patents, received a BS in Chemical
Engineering from Drexel University in 1986, an MS in Biochemical Engineering from Drexel University
in 1988, and an MBA in Finance in 1992 from Indiana University.
What is Joseph S. Zakrzewski's net worth?
The estimated net worth of Joseph S. Zakrzewski is at least $0.00 as of January 18th, 2024. Mr. Zakrzewski owns 405,880 shares of Cytec Industries stock worth more than $0 as of April 23rd. This net worth evaluation does not reflect any other assets that Mr. Zakrzewski may own. Learn More about Joseph S. Zakrzewski's net worth.
How do I contact Joseph S. Zakrzewski?
Has Joseph S. Zakrzewski been buying or selling shares of Cytec Industries?
Joseph S. Zakrzewski has not been actively trading shares of Cytec Industries during the past quarter. Most recently, on Wednesday, December 7th, Joseph S. Zakrzewski bought 21,202 shares of Cytec Industries stock. The stock was acquired at an average cost of $1.30 per share, with a total value of $27,562.60. Following the completion of the transaction, the director now directly owns 154,618 shares of the company's stock, valued at $201,003.40. Learn More on Joseph S. Zakrzewski's trading history.
Are insiders buying or selling shares of Cytec Industries?
In the last twelve months, insiders at the specialty chemicals company sold shares 10 times. They sold a total of 258,914 shares worth more than $668,384.33. The most recent insider tranaction occured on July, 19th when Major Shareholder Holdings A/S Novo sold 1,900 shares worth more than $5,244.00. Insiders at Cytec Industries own 14.4% of the company.
Learn More about insider trades at Cytec Industries. Information on this page was last updated on 7/19/2023.
